Thomson Reuters Collaborates with Orion Bionetworks

Thomson Reuters Collaborates with Orion Bionetworks to Advance the Understanding of
Multiple Sclerosis

Alliance to develop predictive disease models will advance and speed the development of new MS
PHILADELPHIA, October 22, 2013 – The Intellectual Property & Science business of Thomson Reuters, the
world’s leading provider of intelligent information for businesses and professionals, today announced a
collaboration with Orion Bionetworks to further the understanding of multiple sclerosis (MS) and advance the
development of new therapies by generating predictive models of patient stratification and drug targets.

Orion Bionetworks is an alliance of leading organizations in patient care, computational modeling,
translational research, and patient advocacy dedicated to transforming the study of brain disorders and
accelerating the discovery of new therapies and the search for cures. In this project focused on advancing
the understanding of the underlying biology of MS, the members of the alliance will combine their expertise
and assets including biomarkers, disease system biology, high performance computing information
technology and big data analytics to integrate and interpret clinical, molecular, imaging and real-world patient
data to develop new predictive models for the disease.

“We are pleased to welcome Thomson Reuters, which brings unique modeling capabilities that will help
advance our shared goal of accelerating the search for cures for MS,” said Magali Haas, founder and chief
executive officer of Orion Bionetworks. “This collaboration further underscores the importance of building a
robust computational modeling community with diverse expertise and assets to help realize the promise of
predictive modeling in disease research.”

Thomson Reuters Life Sciences Professional Services researchers use MetaBase, the company’s flagship,
manually curated database of protein interactions, biological pathways, disease biomarkers and medicinal
chemistry, along with its unique collection of MS specific pathway maps and biomarkers, to construct
predictive models that identify molecular subtypes, biomarkers, associated mechanisms and novel drug

Thomson Reuters will provide Orion Bionetworks with the results of the modeling through access to the new
MetaBase MS pathways and networks via the Thomson Reuters MetaCore platform, an integrated software
suite for functional data analysis. The models will also be made available to the Alliance through tranSMART,
an open source data sharing and analytics platform.

“We are pleased to be collaborating with Orion Bionetworks on this initiative and providing both our research
expertise and the most authoritative content on biological pathways and molecular interactions,” said Joe
Donahue, senior vice president, Thomson Reuters Life Sciences. “Their cooperative research model brings
together academic groups, non-profit institutions and commercial companies to focus on specific diseases,
with the promise of developing new therapies faster.”

Thomson Reuters Life Sciences Professional Services is a multi-disciplinary team of molecular biologists,
bioinformaticians, medicinal chemists and data scientists. Learn more about Thomson Reuters Life Sciences
Professional Services.

Orion Bionetworks
Orion Bionetworks is a multi-institution cooperative non-profit alliance that is unlocking the power of shared
data and predictive modeling to help transform our understanding of diseases such as multiple sclerosis
(MS) and accelerate the search for cures. Alliance partners include leading organizations in patient care,

computational modeling, translational research, and patient advocacy: Accelerated Cure Project for Multiple
Sclerosis, the Institute for Neurosciences at Brigham and Women’s Hospital, GNS Healthcare, MetaCell,
PatientsLikeMe, Rancho Biosciences, and Thomson Reuters. For more information, go to

Thomson Reuters
Thomson Reuters is the world’s leading source of intelligent information for businesses and professionals.
We combine industry expertise with innovative technology to deliver critical information to leading decision
makers in the financial and risk, legal, tax and accounting, intellectual property and science and media
markets, powered by the world’s most trusted news organization. With headquarters in New York and major
operations in London and Eagan, Minn., Thomson Reuters employs approximately 60,000 people and
operates in over 100 countries. Thomson Reuters shares are listed on the Toronto and New York Stock
Exchanges. For more information, go to www.thomsonreuters.com